IDEA Collider
About
Available on
Community
53 episodes
Welcome to another episode of Idea Collider with your host, Mike Rea. In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics. Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape. Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future. Chapter Summaries [0:00:21 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=21s] Introduction to today's guest, Dr. Nedim Pipic [0:04:23 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=263s] Discussion on Innovation and Growth Mindset [0:06:44 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=404s] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health [0:08:25 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=505s] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs [0:14:39 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=879s] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms [0:16:39 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=999s] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture [0:18:52 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=1132s] Discussion on Innovation and R&D in Pharmaceutical Industry [0:20:22 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=1222s] Driving Innovation and Culture in a Private Pharmaceutical Company [0:23:41 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=1421s] Insights on Innovation and Transformation [0:25:46 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=1546s] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation [0:27:04 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=1624s] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation [0:33:28 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=2008s] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration [0:36:06 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=2166s] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability [0:37:39 https://www.youtube.com/watch?v=3s3sQPyRW_A&t=2259s] Closing Remarks Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Dr. Nedim Pipic; ● LinkedIn: https://www.linkedin.com/in/nedim-pip... https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbVpDWHVVWFJSczNjS3NRQjJ6VzdmWnpvTHgzUXxBQ3Jtc0ttOTNxOGRVaEFHX2N4Sk80UWozNmxjUFFScjk1M2w4aHJvYVdpazBiRUVRQkpGYWVEZkNXc3NhTE5jZmp1MWtBeERaZUlSVDlfTWJaNzJ5S1F1VTFtWHhpYzZieUVmNjYxQ0JhWVdQaFhjRm1fc3hFNA&q=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fnedim-pipic-md-msc-1038812&v=3s3sQPyRW_A ● Website: http://www.boehringer-ingelheim.com https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa3R4ajktMW9uNmUtbkFnREdPMTh3Y1VCLUhXd3xBQ3Jtc0tsNzNTWXRFMlZVYllTRzhhOTZsd193SHRxNF9wN3ZxdDJaYWx6S0FtaTBNVENYbHczVDU5TnpYQXZ5YjVXVzZBZWRsTjVEQzBwOVlIb2hJNnZoTHNaSmljMUYzZy1FV2E1SXRzT05PVWZBWUtzNk91OA&q=http%3A%2F%2Fwww.boehringer-ingelheim.com%2F&v=3s3sQPyRW_A Follow Mike Rea On; ● Website: https://www.ideapharma.com/ https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa3dodUpDT3NDSWJiMEhuTW0xQmhtMF8weUtYd3xBQ3Jtc0ttdHJVN2h0MEExbkJ3Q0RlY1lXTGJIMnlaV2draXlkTnZ0eGdXV2xocFpJZ0M3eExHWU9tSjR6a3MycUNIRUJDMFZkMkktQ2w2MFg3Q052d3N1emswRGZKSlNXY2JtWHhXYlpfU3ZnM0cwTFQ1UExzdw&q=https%3A%2F%2Fwww.ideapharma.com%2F&v=3s3sQPyRW_A ● Twitter: https://twitter.com/ideapharma https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqblVFVmYtTy1lWGhJTFAxRXRzb3Axa281YXFuQXxBQ3Jtc0tsZ0J5cDZaZHNTaVJKV2w0QTNNX1kybWJVOWpFR2UyVmJPdzRxbXVxMVQ3enF1MVVEZlgxRjgxZkYxWl9SMTlPbjVaemRxWHFMNTlZQ2xKZGZGTnlSdTExVVZEcVBBazRvRTVUMWpFSU1MSHFRcmhEWQ&q=https%3A%2F%2Ftwitter.com%2Fideapharma&v=3s3sQPyRW_A ● LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqazBWMnpHbjJJb2MyWXptY09sZWI0bU5VSDA0d3xBQ3Jtc0tscUJ1Mjhpdkd6ZWNFeEJSem1uSl81OHFZTFQzQ3VybzQ2SGFPcV9yNjFYWFcyN25BWGdlNWoyZ1BBMzF3Y19wUjBLQzZXNGU5WjMwUHZqaGl6aWJoaDZISnNtMl9MaUZJV014NE9oaWg5SVhtS0lPaw&q=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fbigidea%2F&v=3s3sQPyRW_A Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa0g0czYybDBRX0VYbGt6VDMzakYzcTBKMHA4d3xBQ3Jtc0ttQjJycU52cGIya3lLOU9kR09DTURWczVmRWdQNzlFYl9hVHhGMGpldlpsLTMzY2JkdC1QZkFNcmtHTDh2c0JobFhlbmJVRVhNOGI3WXR5b0ZMRURpdTRfT2djLVFfRHRNOU1SNEdpaWttMlZib3Q2NA&q=https%3A%2F%2Fpodcast.ideapharma.com%2F&v=3s3sQPyRW_A Don’t forget to Subscribe, Rate, Review, Like, and Share! To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbHdfNUxDX1hxODdGVU5LVTUxcjFiVDBiZF9jUXxBQ3Jtc0trOUxkOXZyY1B4ZF9MUE9sY1lTX3RNaGw5TlJiZTNKd2l1R1UxVDJKbTFqUC01bTVQZVpxM2ZWVEJ0SVl4eEotd3kzTlpiODlHYkppd3JEeWFjRGNMOVBZTzRKcjFOc3JpRllBaV9iSUxhM1ZXa3lXUQ&q=https%3A%2F%2Fpodcast.ideapharma.com%2F&v=3s3sQPyRW_A
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, “Quit: The Power of Knowing When to Walk Away.” https://www.amazon.com/Quit-Power-Knowing-When-Walk/dp/0593422996? Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education https://alliancefordecisioneducation.org/?, a non-profit whose mission is to improve lives by empowering students through decision skills education. In the episode, Annie Duke delves into the motivation behind her latest book, “Quit,” when quitting is a valuable option rather than sticking around, grit versus willingness to quit, and Stewart’s Butterfield’s Quit story before founding Slack. In addition, Annie expounds on the fear of changing your mind and why most people worry about failing instead of winning. Ultimately, she delves into the Monkey & Pedestal Model, three reasons behind building the pedestal, the kill criteria & why you should have a quitting coach! Tune in for more! During this episode, you will learn about; [00:00:33] Introducing today’s guest [00:01:37] What motivated Annie in writing her book Quit as opposed to Thinking in Bets that lead to decision making [00:06:40] The difference between grit & willingness to quit [00:09:27] Why eight times more people die on the descent of Mt. Everest than climbing [00:18:53] Muhammad Ali is the embodiment of showing how in one circumstance, Grit can be a virtue & in the other circumstance, a downfall [00:30:20] Stewart Butterfield’s story from one of the world’s greatest quitter to founding Slack [00:39:37] The fear of changing your mind & failing [00:48:36] The monkey & pedestal model [00:56:18] Three reasons behind building the pedestal [01:02:38] The kill criteria & the idea of having a quitting coach [01:10:08] Does Annie act as a quitting coach? [01:18:51] The Reverse Sicilian concept [01:20:17] How to connect with Annie Duke DON’T FORGET TO FOLLOW, RATE, REVIEW, LIKE, AND SHARE MENTIONED BOOKS __ __ Let’s Connect! FOLLOW ALLIANCE FOR DECISION EDUCATION; __ __ FOLLOW ANNIE DUKE; __ __ More Products FOLLOW MIKE REA ON; __ __ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor. In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the company’s mission of decoding biology to radically improve lives, the relatability of data, and how Recursion builds its various data sets for drug discovery. Moreover, he expounds on how Recursion stands out against its competitors in the tech industry, the unique demographics of the Recursion team, and what differentiates Recursion from other AI discovery companies. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:23] Introducing today’s episode [01:29] About Michael Secora and Recursion as it is today [04:58] Recursion’s Mission on decoding biology to improve lives radically [08:48] Biotechnology versus BioPharma Companies [15:00] Relatability of Data [17:10] Recursion’s data sets & their contents [22:13] How many terabytes of data are they in executing each experiment [24:15] How Recursion stands out against competitors in the Tech environment [26:23] Michael’s approach to humility in the pharmaceutical industry [28:28] Demographics of the Recursion team [31:20] Recursion’s Hack Week [34:51] The difference between AI discovery companies & Recursion [40:11] A hint of Recursion incredible speed in delivering value proposition [47:47] Michael’s Book Recommendations [50:16] How to connect with Michael & Recursion` DON’T FORGET TO Follow, Rate, Review, Like, and Share! MENTIONED BOOKS __ __ LET’S CONNECT! Follow Recursion on; __ __ FOLLOW MICHAEL SECORA __ __ MORE PRODUCTS Follow Mike Rea on; __ __ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care. Companies such as Openwater https://www.openwater.cc/, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater https://www.openwater.cc/ has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke. In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater https://www.openwater.cc/ shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company. Tune in for more insights! Key Highlights [01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory [03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook [05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners [07:32] Why the One Laptop Per Child (OLPC) initiative didn’t work [09:35] How she co-created the world’s first holographic video system from an idea that seemed impossible [12:07] Physicists’ predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologists’ culture of looking for any proof that they are right [17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy [18:24] How did Openwater https://www.openwater.cc/ start, and what does the company deal with? [20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims [26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation [31:42] The side effect of psychedelics in depression treatment [37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry [40:21] The operating and hiring principles of the Openwater https://www.openwater.cc/ company [49:00] How to link with Mary Lou Jepsen DON’T FORGET TO FOLLOW, RATE, REVIEW, LIKE, AND SHARE! LET’S CONNECT! FOLLOW MARY LOU JEPSEN ON HER; __ __ MORE PRODUCTS FOLLOW MIKE REA ON; __ __ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show. She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins. Moreover, she explains that it’s not about prices but your value proposition, understanding your customers' top three buying criteria, and competitive positioning. Ultimately she discusses the power of competitive advantage, implementing metrics that quantify competitive ads and focusing on the company rather than product advantage. TUNE IN FOR MORE! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:20] Introducing today’s episode [01:27] About today’s guest, “Jaynie Smith.” [05:05] The process of unpacking & looking for opportunities [09:44] Does everyone in business understand why they are in business [11:45] Competitive advantage is closing deals & making money in an organization [13:43] Why companies don’t spend enough time listening to their customers [16:09] Building your value proposition [22:28] Competitive positioning [26:05] Do people give positioning the credit that’s due in the business world [30:48] Do ad agencies get competitive positioning right? [32:20] Company versus product competitive advantage [35:57] Why companies lose sight of things that matter most to their customers [38:52] Persistence in communication [40:58] How to connect with Jaynie Smith [41:40] Book recommendations from Jaynie LET’S CONNECT! Follow Jaynie Smith on; __ __ Follow Smart Advantage __ __ MORE PRODUCTS Follow Mike Rea on; __ __ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy https://valorcompounding.com/about-valor/. She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine. Additionally, she delves into the major functional areas of compounding pharmacy, the reasons behind the decline in compounding pharmacy over the years, her source of ideas, and how she judges success. Moreover, Sherine expounds on the organizational structure within the pharmacy, how far she plans into the future, and her journey in business consulting. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [01:23] About Sherine Khalil [05:36] Sherine’s transition from the nonprofit world to academic medicine [11:25] Is her curiosity self-directional? [13:55] About compounding pharmacy and its major function areas [15:55] Reasons for the decline in compounding pharmacy over the years [19:00] Sherine’s source of ideas. What’s her process of assessing development [21:10] Organizational structure and hierarchy within the pharmacy [22:25] How she judges success. What will work or not work [23:54] How far Sherine plans into the future [28:06] What her Quarter 1 & 2 goals look like for her amidst covid in 2022 [30:13] What’s in Sherine’s organizational structure that makes her more agile than other companies [32:19] Sherine’s biggest idea in telehealth [39:33] Sherine’s journey in business consultancy [44:29] Her source of motivation [46:36] Sherine’s book recommendations [48:04] One thing Sherine wishes she could have been asked [52:13] To connect with Sherine LET’S CONNECT! Follow Sherine Khalil on; __ __ Follow Valor Compounding Pharmacy; __ __ More Products Follow Mike Rea on; ● Website: https://www.ideapharma.com/ https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Dr. Brian Smith, a pharma innovation geek for the past 24 years. He talks about his latest book, “ New Drugs, Fair Prices,” https://www.amazon.com/New-Drugs-Fair-Prices-Pharmaceutical/dp/1032361050 and how to manage the pharmaceutical innovation ecosystem for sustainable and affordable new medicines. Additionally, he delves deep into discovery habitats and how every habitat contributes to the ecosystem for a sustainable and affordable supply of new medicines. Moreover, Brian expounds on an unhealthy ecosystem and three big goals to achieve in our ecosystems. TUNE IN! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:21] Introducing the show [01:17] About Brian Smith [04:41] Brian’s main focus in his latest book, “New Drugs, Fair Prices.” [09:20] A snippet of the introduction to Brian’s new book [14:58] Why the definition of terms was important all the way through his book [18:36] The selection pressure in the industry [18:57] The seven types of habitats and what they need to contribute to the ecosystem [22:30] The innovation habitat [25:00] Brian’s definition of an unhealthy ecosystem [28:46] Three big goals we need to achieve through our ecosystem [33:20] Ecosystems don’t just change. How do you understand and manage them? [42:00] Book recommendations for aspiring innovation and pharmaceutical geeks [46:52] How to connect with Brian Smith LET’S CONNECT! FOLLOW BRIAN SMITH ON; __ __ MORE PRODUCTS FOLLOW MIKE REA ON; ● Website: https://www.ideapharma.com/ https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha https://rapidalpha.com/ joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality. Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha https://rapidalpha.com/, what innovation management entails, and how data works and impacts company decisions. Additionally, he expounds on the right KPIs for pharmaceuticals, platforms & tools for better data organization, creating value for your company as well as the future of data. Tune in for more! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:27] Introducing the episode [00:40] Know our guest “Matthew Wahlrab” [04:47] His career path from intellectual property to where he is now [12:00] How data works [16:55] Defining innovation management [21:16] How data impacts company decisions [22:15] About Matthew's company Rapid Alpha & what they do [24:48] Matthew’s special sources [26:29] Matthew’s approach to Green flags & who should be working where [29:49] Getting your timing right [32:22] The right KPIs for pharmaceuticals [37:49] Platforms & tools for better data organization [43:04] Creating value in an enterprise [47:52] The future of data [51:44] Book recommendations from Matthew [55:45] Best way to connect with Matthew Wahlrab [56:31] One question he wishes to have been asked LET’S CONNECT! Follow Matthew Wahlrab on; __ __ Follow Rapid Alpha on; __ __ More Products Follow Mike Rea on; ● Website: https://www.ideapharma.com/ https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Tim Kight, a long-life student of elite performance, coach, and Focus 3 https://focus3.com/ CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results. Tim delves into the five drivers of organizational greatness, training your team on behavioral skills, rebuilding your company’s culture, and expanding your focus run. Additionally, he talks about replacing old habits with good ones, the twenty square ft principle, and stepping up to become an elite in your team! Tune in for more! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:27] Introducing the show [01:50] Tim’s background & experience in sports & business [05:45] Invention doesn’t become innovation all by itself. What roles teams & organizations play [07:29] 5 drivers for organizational greatness [09:25] Talent recognition in organizations [11:26] What to consider when hiring -Job skills vs. behavior skills. [17:52] Leading with your heart in business [20:43] Rethinking & rebuilding a company’s clear, concise & compelling culture [23:13] A quick contrast between an athletic & business team [26:41] Planning for the future of your business. The known versus the unknown of the company's future. [31:14] Expanding your focus run & 5 questions to ask yourself and your team [35:50] Unlearning to relearn your skill versus replacing old habits with good ones [38:00] Tim’s twenty square ft principle [45:37] A case study on changing culture, discipline & achieving good results [53:00] Stepping up, confronting that default mode, and becoming elite in your team [55:36] To connect with Tim Kight DON’T FORGET TO Follow, Rate, Review, Like, and Share! LET’S CONNECT! Follow Tim Kight on; ● LinkedIn: https://www.linkedin.com/in/michael-secora-phd/https://www.linkedin.com/in/timothykight/ ● Website: https://www.recursion.com/https://focus3.com https://focus3.com/ ● Twitter: @TimothyKight https://twitter.com/TimothyKight ● Email: tim@foucs3.com MORE PRODUCTS Follow Mike Rea on; ● Website: https://www.ideapharma.com/ https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today’s episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization. Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:22] Episode introduction [00:36] Today’s focus; Asymmetric learning and its impact on culture [00:55] Know our guest; John Waid [03:01] What is culture? [05:41] The purpose of an organization [10:36] Examples of companies and their values [14:46] Why he came up with the principle of three values [16:34] The importance of respectful spirit value [19:19] Why you should know your; purpose, mission, values, and principles of behavior [22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions [26:27] Chick-fil-A’s values and culture [32:31] Why one company outperforms the other [37:16] Can culture be built virtually? [40:25] How to start building a successful workplace culture [42:53] Disruption vs Innovation [45:09] How to connect with John Waid LOVE THE SHOW? Follow, Rate, Review, Like, and Share! LET’S CONNECT! Follow John Waid on; Website: https://www.corporatecultureconsulting.com/ https://www.corporatecultureconsulting.com/ LinkedIn: https://www.linkedin.com/in/johnwaid/ https://www.linkedin.com/in/johnwaid/ Facebook: https://www.facebook.com/c3culture/ https://www.facebook.com/c3culture/ MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the world’s top experts on strategy and innovation, Rita McGrath. In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation program, challenges in implementation, and why you need multiple funding sources while championing an idea. Additionally, we delve into making that 10x shift in a company, discovery-driven planning, strategic inflection points & best books she would recommend. Tune in for more innovation insights! [02:01] About Rita McGrath [05:10] Rita’s books [11:55] Tips for building an innovation program [16:10] Why do companies have one innovation process [18:45] Reasons companies prefer false confidence instead of the uncertain approach [27:40] How to get an organization to make a shift to a big place [34:11] Rita’s thoughts on creativity [37:25] Why you should have multiple sources of funding & approval [37:54] Being future forward on failure & interrogating failure [43:48] Problems related to assumptions in planning [49:39] Discovery-driven planning [51:01] Strategic inflection points [55:05] Books Rita would recommend [57:16] This or that question (Disruption or innovation) [58:13] To connect with McGrath MENTIONED BOOKS Seeing Around the Corners By Rita McGrath https://www.amazon.com/Seeing-Around-Corners-Inflection-Business-ebook/dp/B07LC98K6Z Market Busters By Rita McGrath https://www.amazon.com/Marketbusters-Strategic-Exceptional-Business-Growth/dp/1591391237 The End of Competitive Advantage By Rita McGrath https://www.amazon.com/End-Competitive-Advantage-Strategy-Business/dp/1422172813 Discovery-Driven Growth By Rita McGrath https://www.amazon.com/Discovery-Driven-Growth-Breakthrough-Process-Opportunity/dp/1591396859 Seven Rules of Power By Jeffrey Pfeffer https://www.amazon.com/s?k=the+seven+rules+of+power&adgrpid=1342505344382235&hvadid=83906847331319&hvbmt=bp&hvdev=c&hvlocphy=150419&hvnetw=o&hvqmt=p&hvtargid=kwd-83907593042990%3Aloc-98&hydadcr=6589_10182145&tag=mh0b-20&ref=pd_sl_8d86j8xeun_p Thinking Fast & Slow by Kahneman Daniel https://www.amazon.com/Thinking-Fast-Slow-Daniel-Kahneman/dp/0374533555 Humor Seriously By Jennifer A Aker & Naomi Bagdonas https://www.amazon.com/Humor-Seriously-Secret-Business-harness/dp/0593135288 LET’S CONNECT! To Connect With Rita McGrath; ● Website: https://www.recursion.com/https://www.ritamcgrath.com/ ● Website: https://www.linkedin.com/company/recursion-pharmaceuticals/https://www.valize.com/ MORE PRODUCTS Follow Mike Rea on; __ __ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO of Exscientia https://www.exscientia.ai/, as he talks to us about the use of AI in drug discovery. In the episode, we delve into Andrew’s journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integration in the pharmaceutical industry. Additionally, he expounds on what AI drugs look like and future plans for Exscientia. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [01:12] Introducing Andrew Hopkins & his journey to his current role [06:27] Applying data mining approach & machine learning [12:10] What Andrew saw that others were not seeing [19:06] The value of data integration [22:02] The role of asking questions & finding answers in tech or data [26:46] How Hopkins addresses being referred to as the AI discovery group [33:08] Active learning approaches [39:06] What an AI drug looks like & what it’s better at [42:17] The future of AI drugs & Exscientia future plans in establishing clinics [46:34] What do the next couple of years look like regarding solutions Andrew wished he had 5-10 years ago? DON’T FORGET TO Follow, Rate, Review, Like, and Share! MENTIONED BOOKS Ideas-A History From Fire To Freud by Peter Watson https://www.amazon.com/Ideas-History-Freud-Peter-Watson/dp/0753820897 Where Good Ideas Come From by Steven Johnson https://www.amazon.com/s?k=where+the+good+ideas+come+from&adgrpid=1345803619640174&hvadid=84112927367932&hvbmt=be&hvdev=c&hvlocphy=150419&hvnetw=o&hvqmt=e&hvtargid=kwd-84113659996076%3Aloc-98&hydadcr=22591_10459030&tag=mh0b-20&ref=pd_sl_1ng7mckjs7_e LET’S CONNECT! Follow Exscientia on; ● Website: https://www.recursion.com/https://www.exscientia.ai/ ● LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/https://www.linkedin.com/company/ex-scientia/ MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer’s profiteering from the pandemic and the drug pricing in America. John also discusses how Gilead’s Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIH’s role in drug discovery research, and the profitability of the pharma industry. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:22] Introduction to the show [0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books [04:58] Misconception about Pfizer’s profiteering from the pandemic [08:13] Drug pricing in America [12:35] Gilead’s Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries [19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol [21:42] Effect the insurance companies have had on the drug market [26:09] Value of the ‘me-too’ drugs [30:01] The inefficiency of the flu vaccines [33:03] The funding for early-stage mRNA vaccines [34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines [37:46] What is NIH’s role in drug discovery research? [38:13] The process and cost of drug discovery; from idea to getting the drug approved [42:39] Misinformation about insulin and its pricing [47:21] Is the value vs. affordability of medicines a reputation challenge or a commercial challenge for the industry? [51:31] What’s the profitability of the pharma industry? [59:48] Recommended reading [01:02:38] How to connect with us DON’T FORGET TO Subscribe, Rate, Review, Like, and Share! RESOURCES MENTIONED Book; Pharma and Profits by John L. LaMattina https://www.amazon.com/gp/product/B0B33V6B7Y/ref=dbs_a_def_rwt_bibl_vppi_i0 Book; Devalued and Distrusted by John L. LaMattina https://www.amazon.com/gp/product/B00ANR91W8/ref=dbs_a_def_rwt_bibl_vppi_i1 Book; Drug Truths by John L. LaMattina https://www.amazon.com/gp/product/B005CCUCEK/ref=dbs_a_def_rwt_bibl_vppi_i2 Book; The Great American Drug Deal by Peter Kolchinsky https://www.amazon.com/Great-American-Drug-Deal-Prescription/dp/1733058915 LET’S CONNECT! Website: https://www.johnlamattina.com/ https://www.johnlamattina.com/ Twitter: https://twitter.com/john_lamattina https://twitter.com/john_lamattina LinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/ https://www.linkedin.com/in/john-lamattina-2985a9b/ MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. Today we are joined by Gene Yoo, the Chief Executive Officer at Resecurity, Inc. https://resecurity.com/ He talks about asymmetric learning in cybersecurity & Intelligence and what gives Resecurity an edge over other competitors in the market Moreover, he shares about the signal validation process at Resecurity, how to understand the vulnerability of your business and what you need to combat cyber threats. In addition, Gene talks about the ‘what if’ component in their learning approach and the leadership style & culture at Resecurity. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:23] Introduction to the show [01:23] What this series is about; Asymmetric learning [04:41] Definition of insight in cybersecurity [07:07] What is cyber threat intelligence about, and how should threat intelligence data be interpreted to deliver actionable insights? [10:37] Security theater [14:40] How Resecurity identifies a threat [19:58] Understanding the vulnerability of your business and what you need to combat cyber threats [22:52] Do they provide threat solutions or just threat evidence? [24:22] The ‘what if’ component in their learning approach [27:36] What gives Resecurity an edge over other cybersecurity & Intelligence companies in the market? [29:19] Signal validation process at Resecurity [31:00] The source of their data [34:29] Resecurity leadership style and culture [39:40] Prototyping at Resecurity [42:49] Does Gene prefer a disruptor or an innovator? [44:59] What’s the future of Resecurity in 5 years? (46:33] How to connect with Gene Yoo DON’T FORGET TO Subscribe, Rate, Review, Like, and Share! LET’S CONNECT! Follow Gene Yoo on; Website: https://resecurity.com/ https://resecurity.com/ LinkedIn: https://www.linkedin.com/company/resecurity/ https://www.linkedin.com/company/resecurity/ Facebook: https://bit.ly/3vqMfzS https://bit.ly/3vqMfzS Twitter: https://twitter.com/RESecurity https://twitter.com/RESecurity Vimeo: https://vimeo.com/user153388997 https://vimeo.com/user153388997 MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. In today’s episode, Mike interviews Steven Johnson, an author of 13 books, a TV host, and a podcaster. He talks about Innovation vs. Invention and explains where good ideas come from. Additionally, Steven talks about the Individual and organizational hunch collection tools and shares how organizational culture impacts innovation. Moreover, he talks about his books The Ghost Map https://www.amazon.com/Ghost-Map-Londons-Terrifying-Epidemic/dp/1594482691 and Farsighted https://www.amazon.com/Farsighted-Make-Decisions-That-Matter/dp/1594488215. Tune in! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [01:05] Meet Steven Johnson and hear his backstory [03:03] Innovation vs. Invention [05:26] Where do good ideas ‘soul hunches’ come from? [09:32] Reason why play and delight are linked to profound innovation [12:52] Organizational culture and innovation [17:12] How the daily schedule for his writing work looks like [10:1414] Steven’s discovery process [26:59] How Steven uses Twitter as a source of scientific discovery [30:58] Individual and organizational hunch collection tools [39:10] The Ghost Map https://www.amazon.com/Ghost-Map-Londons-Terrifying-Epidemic/dp/1594482691 and how it evolved from the format to a published book [46:34] Farsighted https://www.amazon.com/Farsighted-Make-Decisions-That-Matter/dp/1594488215: How We Make the Decisions That Matter the Most [55:11] How to connect with Steven Johnson REMEMBER TO Follow, Rate, Review, Like, and Share! RESOURCES MENTIONED Book; The Ghost Map by Steven Johnson https://www.amazon.com/Ghost-Map-Londons-Terrifying-Epidemic/dp/1594482691 Book; Farsighted by Steven Johnson https://www.amazon.com/Farsighted-Make-Decisions-That-Matter/dp/1594488215 Book; How We Got to Now by Steven Johnson https://www.amazon.com/gp/product/B00INIXU5I/ref=dbs_a_def_rwt_hsch_vapi_tkin_p1_i2 Book: Wonderland by Steven Johnson https://www.amazon.com/gp/product/B01CZCW2PQ/ref=dbs_a_def_rwt_hsch_vapi_tkin_p1_i9 LET’S CONNECT! Follow Steven Johnson on; Website: https://stevenberlinjohnson.com/ https://stevenberlinjohnson.com/ Twitter: https://twitter.com/stevenbjohnson https://twitter.com/stevenbjohnson Subscribe to his Newsletter at: https://adjacentpossible.substack.com/about https://adjacentpossible.substack.com/about To grab a copy of any of Steven’s Books: https://amzn.to/3L3zUrV https://amzn.to/3L3zUrV MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ https://podcast.ideapharma.com/
Welcome to another fantastic episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Billy Kenber, an investigative journalist at “The Times.” He talks about his journey to writing his book ‘Sick Money’ and the content in the book. Additionally, he talks about the pharmaceutical industry’s social contract with patients and how its distortion has led to pharmaceutical greed. Moreover, he shares how the culture within the pharmaceutical industry has changed, why drug companies overprice the drugs, and what can be done to regulate drug pricing. TUNE IN! DURING THIS EPISODE, YOU WILL LEARN ABOUT; [00:22] Episode introduction [01:08] Meet our guest; Billy Kenber [01:22] His journey to writing his book ‘Sick Money’ [03:28] What the book is about [06:11] How Concordia Pharmaceuticals & Valeant Pharmaceuticals companies grew quickly and gained a short-term monopoly, thus hiking the drug prices [10:40] What’s the geographical scope of the pharmaceutical fraud [12:47] Pharmaceutical industry’s social contract with patients and how its distortion has led to pharmaceutical greed [15:20] The first AIDS drug; AZT [18:30] A background of AZT drug high pricing and how it led to other pharmaceutical companies raising their prices [22:47] How Pharmacy Benefit Managers (PBMs) raise drug prices for patients [25:39] The ’Dirty Pharma’ chapter in his book [28:45] Why drug companies overprice the drugs [29:17] How the culture within the pharmaceutical industry has changed [30:52] Pharmaceutical innovation after World War II; Antibiotics [35:29] mRNA vaccines in the COVID-19 pandemic [37:28] Effect of cultural changes in the pharmaceutical industry on the drugs we get and how Research and Development (R&D) is done [40:30] How cultural changes have affected orphan drugs and cancer drugs [46:30] What can be done to regulate drug pricing? [53:50] Recommended reading [56:00] How to connect with Billy LOVE THE SHOW? FOLLOW, RATE, REVIEW, LIKE, AND SHARE! LET’S CONNECT! FOLLOW BILLY KENBER ON HIS; Website: https://www.billykenber.com/ https://www.billykenber.com/ Twitter: https://twitter.com/billykenber https://twitter.com/billykenber Linkt.ree: https://linktr.ee/billykenber https://linktr.ee/billykenber To grab a copy of the ‘Sick Money’ book: https://amzn.to/3N4XJPD MORE PRODUCTS Follow Mike Rea on; Website: https://www.ideapharma.com/ https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.
(Now also released in paperback: https://amzn.to/3lWjo2B) Kat can be found at First Create The Media https://firstcreatethemedia.com/: and on Twitter: @Kat_Arney Find out more about Rebel Cell here: https://www.rebelcellbook.com/about-rebel-cell-cancer-book Many of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL: Cancer Evolution and the Science of Life, that perception just isn’t true. Although it might be rare in many species, cancer is the enemy lurking within almost every living creature. Why? Because cancer is a bug in the system of life. We get cancer because we can't not get it. Cancer has always been with us. It killed our hominid ancestors, the mammals they evolved from and the dinosaurs that trampled the ground before that. Tumours grow in pets, livestock and wild animals. Even tiny jelly-like Hydra - creatures that are little more than a tube full of water - can get cancer. Cancer starts when cells rebel against the social norms of the body, throwing off their molecular shackles and growing out of control in a shambolic mockery of normal life. This is why we can't avoid cancer: because the very genes that drive it are essential for life itself. The revolution has raged, on and off, for millions of years. But it was only in the twentieth century that doctors and scientists made any significant progress in understanding and treating cancer, and it is only in the past few decades that we’ve finally begun to kick the mob’s malignant arse. Now the game is changing. Scientists have infiltrated cancer's cellular rebellion and are finally learning its secrets. Seeing cancer in a new way – as rebel cells adapting and evolving within the landscape of the body – is pointing towards new ways of preventing and controlling cancer in the long term or even driving it to extinction altogether. In REBEL CELL, geneticist and science writer Kat Arney reveals that: Modern lifestyles can’t take all the blame – Cancer has been around for millions of years and affects almost all multicellular organisms, with some notable exceptions. Sponges and comb jellies are remarkably cancer-resistant, for example, although the reason why is still a mystery. Cancer cells are cheats that break the rules – From cells all the way up to human cities, societies function best when everyone obeys the rules. Cancer cells are cheats in the system, bending or completely breaking the rules to their advantage. Cancer is an inevitable part of life – Genetic alterations (mutations) are the fuel for evolution – the force that shaped all life on earth. But this same force is at work within cancer, enabling them to adapt and evolve resistance to treatment. Mutations are much more common than we thought – As we age, our bodies become a patchwork of mutated cells, yet most of these don’t become cancerous. The big question is why? The quest for a cure has derailed our thinking – Focusing on ‘magic bullets’ and pricey wonder drugs has led us away from potentially transformative approaches to preventing and treating cancer based on evolutionary ideas. REBEL CELL: Cancer Evolution and the Science of Life takes the reader back to the dawn of life on planet earth right up to the present day to get to the heart of what cancer really is and how by better understanding it we might one day overcome it.
As President of Novartis Oncology, Susanne Schaffert is pursuing a bold strategy to reimagine the research, development and commercialization of innovative treatments that will help improve and extend the lives of people with cancer and related blood disorders. Susanne has held positions of increasing seniority across a range of business areas during her career at Novartis, having first joined the company as a sales representative in Germany in 1995. The majority of her roles have been in oncology, where she has a passion for making a difference in the lives of patients. Prior to her current position, she served as President of Advanced Accelerator Applications, a Novartis company focused on the development of products for targeted radioligand therapy and precision imaging. Today, she leads more than 10 000 employees in 85 countries working to transform cancer care across four distinct therapeutic platforms. Susanne is a respected business leader and scientist who was featured in Fortune’s “Most Powerful Women International” list in both 2019 and 2020. She actively mentors women at Novartis and encourages them to seek leadership roles. Susanne has a background in science and holds a doctorate in organic chemistry from the University of Erlangen in Germany, but as a former ballet dancer, she is also passionate about the arts. This dual interest informs her leadership philosophy, which celebrates diversity of thought and ideas as one of the keys to bold innovation. Susanne also holds leadership positions in the broader pharmaceutical industry. She serves on the board and executive committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and is vice chair of EFPIA’s Patient Access Committee. Susanne on LinkedIn: https://www.linkedin.com/in/susanne-schaffert-830b7053
Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development. Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994..
With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible. Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February. From the page at brianchristian.org: A jaw-dropping exploration of everything that goes wrong when we build AI systems and the movement to fix them. Today’s “machine-learning” systems, trained by data, are so effective that we’ve invited them to see and hear for us—and to make decisions on our behalf. But alarm bells are ringing. Recent years have seen an eruption of concern as the field of machine learning advances. When the systems we attempt to teach will not, in the end, do what we want or what we expect, ethical and potentially existential risks emerge. Researchers call this the alignment problem. Systems cull résumés until, years later, we discover that they have inherent gender biases. Algorithms decide bail and parole—and appear to assess Black and White defendants differently. We can no longer assume that our mortgage application, or even our medical tests, will be seen by human eyes. And as autonomous vehicles share our streets, we are increasingly putting our lives in their hands. The mathematical and computational models driving these changes range in complexity from something that can fit on a spreadsheet to a complex system that might credibly be called “artificial intelligence.” They are steadily replacing both human judgment and explicitly programmed software. In best-selling author Brian Christian’s riveting account, we meet the alignment problem’s “first-responders,” and learn their ambitious plan to solve it before our hands are completely off the wheel. In a masterful blend of history and on-the ground reporting, Christian traces the explosive growth in the field of machine learning and surveys its current, sprawling frontier. Readers encounter a discipline finding its legs amid exhilarating and sometimes terrifying progress. Whether they―and we―succeed or fail in solving the alignment problem will be a defining human story. The Alignment Problem offers an unflinching reckoning with humanity’s biases and blind spots, our own unstated assumptions and often contradictory goals. A dazzlingly interdisciplinary work, it takes a hard look not only at our technology but at our culture―and finds a story by turns harrowing and hopeful. Read more at: https://brianchristian.org/the-alignment-problem/
Syn is an award winning music agency and creative solutio, providing music strategy, composition, sound design and sonic branding for advertising, cinema and television, as well as music supervision, licensing and music curation services and our studios record voiceover, ADR and narration. In this interview, we discuss the user experience (patient, physician), via sound, for healthcare and pharma environments More information at https://syn.world
Great interview with Riccardo on CNBC https://www.cnbc.com/riccardo-zacconi-hitting-the-sweet-spot/ Find out more about PTEN Research at https://www.ptenresearch.org
Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com
A discussion of The Playbook, from DiMe Society, Digital Clinical Measures Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health https://playbook.dimesociety.org More on Andy (Andrea) Coravos here: http://www.andreacoravos.com More on Jen (Jennifer) Goldsack here: https://en.wikipedia.org/wiki/Jennifer_Goldsack More on DiMe Society here: https://www.dimesociety.org
CARINNE BROUILLON is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit Professional milestones __ __ EDWARD HÆGGSTRÖM Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015. Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology. Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN. ROB SCOTT, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. During his career he has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Before retiring, his most recent position was Chief Medical Officer and Head of Development at AbbVie where he had oversight on all early and late-stage development programs. He was also responsible for a team of over 4,000 employees spanning 52 countries, a budget of close to $2 billion and programs involving approximately 40 new molecular entities. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen where he was responsible for the development of evolocumab (Repatha) the first approved PCSK9 inhibitor, ivabradine (Corlanor), to treat heart failure and omecamtiv mecarbil, a direct myosin activator for heart failure. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies. Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He is a board member of Transclerate and a member of the PhRMA R&D Leadership Forum.
This episode replays some of a round table we held at JP Morgan, back when people used to travel... It features the voices of Mike Rea, in conversation with Linda Avey, Co-founder of 23andMe, and Curious, Inc, Amrit Chaudhuri, CEO, Mass Innovation Labs (now SmartLabs), Steve Holtzman, then CEO, Decibel Therapeutics, Raj Kannan then SVP, Global Franchise Head, Neurology & Immunology, EMD Serono, Michael Schrage, Research Fellow, MIT Center for Digital Business; Visiting Fellow, Imperial College Department of Innovation and Entrepreneurship, and Robert Urban, then Global Head, Johnson & Johnson Innovation Do head to our YouTube channel for more from this round table, and to see which voice belongs to which speaker...
ABOUT THE INNOVATION DELUSION Innovation is the hottest buzzword in business. But what if our obsession with finding the next big thing has distracted us from the work that matters most? “The most important book I’ve read in a long time . . . It explains so much about what is wrong with our technology, our economy, and the world, and gives a simple recipe for how to fix it: Focus on understanding what it takes for your products and services to last.”—Tim O’Reilly, founder of O’Reilly Media It’s hard to avoid innovation these days. Nearly every product gets marketed as being disruptive, whether it’s genuinely a new invention or just a new toothbrush. But in this manifesto on thestate of American work, historians of technology Lee Vinsel and Andrew L. Russell argue that our way of thinking about and pursuing innovation has made us poorer, less safe, and—ironically—less innovative. Drawing on years of original research and reporting, The Innovation Delusion shows how the ideology of change for its own sake has proved a disaster. Corporations have spent millions hiring chief innovation officers while their core businesses tank. Computer science programs have drilled their students on programming and design, even though theoverwhelming majority of jobs are in IT and maintenance. In countless cities, suburban sprawl has left local governments with loads of deferred repairs that they can’t afford to fix. And sometimes innovation even kills—like in 2018 when a Miami bridge hailed for its innovative design collapsed onto a highway and killed six people. In this provocative, deeply researched book, Vinsel and Russell tell the story of how we devalued the work that underpins modern life—and, in doing so, wrecked our economy and public infrastructure while lining the pockets of consultants who combine the ego of Silicon Valley with the worst of Wall Street’s greed. The authors offer a compelling plan for how we can shift our focus away from the pursuit of growth at all costs, and back toward neglected activities like maintenance, care, and upkeep. For anyone concerned by the crumbling state of our roads and bridges or the direction our economy is headed, The Innovation Delusion is a deeply necessary reevaluation of a trend we can still disrupt.
Peter B. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year. In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer. Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered. Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006. Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes. View a comprehensive list of media coverage of Dr. Bach and his work. Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008. In 2020, Dr. Bach co-founded EQRx, a biotechnology startup focused on developing affordable drugs. He currently serves an advisory role within the organization. Further information at: https://drugpricinglab.org/about/ or https://www.mskcc.org/news/media-coverage?keys=Peter+bach
